Poster: A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a Cerebrospinal Fluid Biomarker for Mucopolysaccharidosis II Disease
Accumulation of dermatan sulfate (DS) in tissue and body fluid leads to mucopolysaccharidosis II (MPS II) disorder. The study aims to develop an LC-MS/MS assay to measure DS in human cerebrospinal fluid (CSF) as a biomarker.
Case Study: Clinical Study of Abuse-Deterrent Formulation to Suppress Release of Hydrocodone
Chronic pain affects millions of Americans, with a prevalence higher than heart disease, cancer, and diabetes combined. Chronic pain resulting in osteoarthritis and cancer is often treated with opioid medications. Opioid medications can provide short-, intermediate-, or long-acting analgesia. Hydrocodone is one of the currently approved formulations available in IR and ER forms. Extended-release forms are formulated as both combination products with acetaminophen or non-steroidal anti-inflammatory drugs or single-entity drug. All currently approved oral opioids have limitations, including continued concern about abuse and misuse in the intended patient population. Like other opioids used in analgesia, hydrocodone can be abused and is subject to criminal diversion. A number of the abuse-deterrent formulations in development and available on the market utilize hard-to-crush tablet technologies.
Fact Sheet: CMC GMP Analytical Testing
Biologics or biopharmaceuticals are inherently more complex than small-molecule drugs. You need the right team to help you. Frontage has expertise and state of the art instrumentation necessary for the analytical method development, validation and transfer for complex biopharmaceutical compounds. Using bottom up, middle up/down, and top down approaches, we offer analytical support for characterization of primary, secondary and tertiary structures, post translational modifications such as glycosylation, disulfide linkage, antibody drug conjugation, or PEGylation.
Corporate Deck: Frontage Laboratories Overview Deck 08.2019
We are a CRO providing integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance. We have successfully assisted clients to advance hundreds of molecules through development to commercial launch in global markets.